Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded by StockNews.com to “Strong-Buy”

StockNews.com upgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a buy rating to a strong-buy rating in a research report released on Thursday.

Other research analysts have also recently issued research reports about the company. Needham & Company LLC reduced their target price on Jazz Pharmaceuticals from $222.00 to $210.00 and set a buy rating on the stock in a report on Thursday, June 20th. Stifel Nicolaus lifted their target price on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a buy rating in a report on Friday, March 15th. Royal Bank of Canada reiterated an outperform rating and issued a $195.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. Truist Financial reiterated a buy rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Finally, JPMorgan Chase & Co. lifted their target price on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an overweight rating in a report on Friday, March 22nd. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average target price of $190.00.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $106.73 on Thursday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. The stock has a fifty day moving average of $108.93 and a two-hundred day moving average of $116.67. The company has a market capitalization of $6.73 billion, a price-to-earnings ratio of 22.01, a PEG ratio of 1.64 and a beta of 0.62. Jazz Pharmaceuticals has a fifty-two week low of $103.01 and a fifty-two week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.53 by ($1.55). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The business had revenue of $901.98 million for the quarter, compared to analyst estimates of $938.99 million. On average, analysts anticipate that Jazz Pharmaceuticals will post 15.35 EPS for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the completion of the transaction, the executive vice president now directly owns 36,629 shares in the company, valued at $4,016,369.85. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 4.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its position in Jazz Pharmaceuticals by 0.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company’s stock worth $1,937,000 after purchasing an additional 99 shares during the period. Waterfront Wealth Inc. lifted its position in Jazz Pharmaceuticals by 1.2% in the fourth quarter. Waterfront Wealth Inc. now owns 8,633 shares of the specialty pharmaceutical company’s stock worth $1,062,000 after purchasing an additional 103 shares during the period. ProShare Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 1.4% in the first quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock valued at $896,000 after buying an additional 105 shares in the last quarter. Prime Capital Investment Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 4.3% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company’s stock valued at $325,000 after buying an additional 108 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board increased its holdings in shares of Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 29,749 shares of the specialty pharmaceutical company’s stock valued at $3,659,000 after buying an additional 108 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.